Physician profile
Antonio Castillo
NPI 1639388481
$592.86
in general payments reported to CMS, 2019-2025
12 companies · $85.20 in 2025
The $85.20 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.80 · 2020: $16.83 · 2021: $134 · 2022: $31.43 · 2023: $131 · 2024: $176 · 2025: $85.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $392.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Protega Pharmaceutials INC | $123.40 | 2024-2025 | Roxybond |
| Collegium Pharmaceutical, INC. | $90.72 | 2021-2024 | Xtampza, Belbuca |
| Spr Therapeutics, INC | $80.06 | 2024 | Sprint Pns System |
| Idorsia Pharmaceuticals US INC | $77.98 | 2023-2024 | Quviviq |
| Redhill Biopharma INC. | $70.50 | 2021 | |
| Grt US Holding, INC. | $45.00 | 2021 | |
| Abbvie INC. | $24.17 | 2023 | Vraylar |
| Vertex Pharmaceuticals Incorporated | $19.17 | 2024 | |
| Novartis Pharmaceuticals Corporation | $17.80 | 2019 | |
| Ibsa Pharma INC. | $16.83 | 2020 | |
| Hikma Pharmaceuticals USA | $13.92 | 2022 | |
| Lilly USA, LLC | $13.31 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.